Purple Biotech Ltd.-ADRPPBT
13F holders, Q1 2025 (March 31)8holders −5
1new positions
5sold out
$2.65avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Purple Biotech Ltd.-ADR (PPBT) in their 13F filings, down 5 from Q4 2024. 1 opened new positions and 5 sold out. The largest holders were UBS Group AG ($61K), Kingswood Wealth Advisors, LLC ($44K) and BNP Paribas Financial Markets ($14K).
- Company
- Purple Biotech Ltd.-ADR
- CUSIP
- 74638P208
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $226 |
| Exits | 5 | $116K |
All 13F filers, Q4 2024 → Q1 2025: 12,527 shares bought and 42,284 shares sold, net −29,757 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| UBS Group AG | 0.00% | Add +113.5% | 23,025 | $61K |
| Kingswood Wealth Advisors, LLC | 0.00% | Reduce -50.0% | 16,797 | $44K |
| BNP Paribas Financial Markets | 0.00% | No change | 5,375 | $14K |
| Morgan Stanley | 0.00% | Reduce -12.7% | 4,466 | $12K |
| Rhumbline Advisers | 0.00% | Add +33.1% | 805 | $2K |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 85 | $226 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -89.5% | 20 | $53 |
| Royal Bank of Canada | 0.00% | No change | 107 | $0 |
"% of holder's portfolio" is PPBT's weight in each manager's 13F, not the share of Purple Biotech Ltd.-ADR the manager owns.